pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

12,161 catalysts · 3,603 8k filing · 2,283 grant · 1,765 approval · 1,146 device 510k · 1,000 device adverse event · 827 device pma

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 0 catalysts2026-08-27: 0 catalysts2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 1 catalyst2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 2 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 1 catalyst2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 2 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 1 catalyst2026-10-14: 1 catalyst2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 1 catalyst2026-10-20: 2 catalysts2026-10-21: 2 catalysts2026-10-22: 2 catalysts2026-10-23: 1 catalyst2026-10-24: 0 catalysts2026-10-25: 0 catalysts2026-10-26: 1 catalyst2026-10-27: 8 catalysts2026-10-28: 12 catalysts2026-10-29: 21 catalysts2026-10-30: 4 catalysts2026-10-31: 0 catalysts2026-11-01: 0 catalysts2026-11-02: 9 catalysts2026-11-03: 18 catalysts2026-11-04: 22 catalysts2026-11-05: 37 catalysts2026-11-06: 2 catalysts2026-11-07: 0 catalysts2026-11-08: 0 catalysts2026-11-09: 1 catalyst2026-11-10: 0 catalysts2026-11-11: 0 catalysts2026-11-12: 0 catalysts2026-11-13: 0 catalysts2026-11-14: 0 catalysts2026-11-15: 0 catalysts2026-11-16: 0 catalysts2026-11-17: 0 catalysts2026-11-18: 0 catalysts2026-11-19: 0 catalysts2026-11-20: 0 catalysts2026-11-21: 0 catalysts2026-11-22: 0 catalysts
view
agendamonth
sort
soonestlatesttypesponsoralpha
from 2025-12-05×clear all
type
  • 8k filing3,603
  • grant2,283
  • approval1,765
  • device 510k1,146
  • device adverse event1,000
  • device pma827
device recall
606
  • earnings585
  • recall266
  • phase 2 completion172
  • therapy area
    • Oncology148
    • Infectious Disease46
    • Cardiology37
    • Immunology35
    • Dermatology31
    • Pulmonology22
    • Women's Health19
    • Ophthalmology16
    • Pain15

    Week of Dec 15, 2025

    20
    ›Dec 19, 2025device recall253d agoSiemens Medical Solutions USA, Inc device recall (Cls II)

    NAEOTOM Alpha Software applications: syngo.CT Brain Quantification syngo.CT Vessel Hyperdensities syngo.CT ASPECTS — Reason: To remove the software applications from certain CT systems as the applications have not received FDA 510(k) clearance. — Status: Ongoing

    full page →fda device recalls ↗
    ›Dec 19, 2025device recall253d agoCanon Medical System, USA, INC. device recall (Cls II)

    Alphenix INFX-8000H, interventional fluoroscopic x-ray system — Reason: It has been discovered that there is a possibility that the fixing screws of the ceiling movement gear in the ceiling suspended arm that are part of the X-ray interventional systems may become loose. As a result, ceiling lateral movement may no longer be possible, abnormal noise may be generated from the suspension system and a sensor error may be displayed — Status: Ongoing

    full page →fda device recalls ↗
    ›Dec 19, 2025device recall253d agoBoston Scientific Corporation device recall (Cls I)BOSTON SCIENTIFIC CORP

    *HOT AXIOS Stent and Electrocautery-Enhanced Delivery System 8mm x 8mm; Material Number (UPN): M00553530; — Reason: Increased reports of stent deployment and expansion issues. The most common outcome reasonably foreseeable resulting from difficulty deploying the stent is prolongation of the procedure to exchange the device for a new one. The most serious reasonably foreseeable outcome in cases where the first flange is unable to deploy or expand would be a cascade of events resulting in additional intervention, either endoscopic or surgical, to remove the stent and close the puncture site. — Status: Ongoing

    full page →fda device recalls ↗
    ›Dec 19, 2025device recall253d agoCanon Medical System, USA, INC. device recall (Cls II)

    Alphenix INFX-8000V, interventional fluoroscopic x-ray system — Reason: It has been discovered that there is a possibility that the fixing screws of the ceiling movement gear in the ceiling suspended arm that are part of the X-ray interventional systems may become loose. As a result, ceiling lateral movement may no longer be possible, abnormal noise may be generated from the suspension system and a sensor error may be displayed — Status: Ongoing

    full page →fda device recalls ↗
    ›Dec 19, 2025device recall253d agoBoston Scientific Corporation device recall (Cls I)BOSTON SCIENTIFIC CORP

    AXIOS Stent and Electrocautery-Enhanced Delivery System - 8mm x 8mm; Material Number (UPN): M00553690; — Reason: Increased reports of stent deployment and expansion issues. The most common outcome reasonably foreseeable resulting from difficulty deploying the stent is prolongation of the procedure to exchange the device for a new one. The most serious reasonably foreseeable outcome in cases where the first flange is unable to deploy or expand would be a cascade of events resulting in additional intervention, either endoscopic or surgical, to remove the stent and close the puncture site. — Status: Ongoing

    full page →fda device recalls ↗
    ›Dec 19, 2025device recall253d agoAltruan GmbH device recall (Cls II)

    Brand Name: Bisaf Strep A Self-Test. Test for detection of group A streptococcal antigens in throat swabs. — Reason: Product not cleared by the FDA. — Status: Ongoing

    full page →fda device recalls ↗
    ›Dec 19, 2025device recall253d agoTyber Medical device recall (Cls II)

    Brand Name: VOLT" Wrist Treatment System Product Name: 2.4/2.7 2Column Dist Radius Plate 6Hd/10Shaft/Left/Std/139mm Model/Catalog Number: 02.426.681S Product Description: 2 Column Distal Radius Plate - 6 Head, 10 Shaft, Standard Left - 139mm — Reason: The supplier manufactured anatomical left plates with an incorrect thread orientation. — Status: Ongoing

    full page →fda device recalls ↗
    ›Dec 19, 2025device recall253d agoCanon Medical System, USA, INC. device recall (Cls II)

    Alphenix INFX-8000C, interventional fluoroscopic x-ray system — Reason: It has been discovered that there is a possibility that the fixing screws of the ceiling movement gear in the ceiling suspended arm that are part of the X-ray interventional systems may become loose. As a result, ceiling lateral movement may no longer be possible, abnormal noise may be generated from the suspension system and a sensor error may be displayed — Status: Ongoing

    full page →fda device recalls ↗
    ›Dec 19, 2025device recall253d agoSiemens Medical Solutions USA, Inc device recall (Cls II)

    NAEOTOM Alpha.Prime Software applications: syngo.CT Brain Quantification syngo.CT Vessel Hyperdensities syngo.CT ASPECTS — Reason: To remove the software applications from certain CT systems as the applications have not received FDA 510(k) clearance. — Status: Ongoing

    full page →fda device recalls ↗
    ›Dec 19, 2025device recall253d agoAltruan GmbH device recall (Cls II)

    Wondfo Streptococcal A At-Home Self-Test. At-home test for group A beta-hemolytic streptococcal infection. — Reason: Product not cleared by the FDA. — Status: Ongoing

    full page →fda device recalls ↗
    ›Dec 19, 2025grant253d agoNEW YORK UNIVERSITY SCHOOL OF MEDICINE — Plasticity and social neuromodulation of developing auditory cortical circuitsNew York University

    DC grant. $134,109. PI: Megan Anne Kirchgessner

    full page →nih reporter ↗
    ›Dec 19, 2025grant253d agoUNIVERSITY OF MINNESOTA — MULTI-ETHNIC STUDY OF ATHEROSCLEROSIS (MESA)University of Minnesota

    HL grant. $794,063. PI: JAMES S PANKOW

    full page →nih reporter ↗
    ›Dec 19, 2025grant253d agoUNIVERSITY OF CONNECTICUT SCH OF MED/DNT — Examining the role of locus coeruleus glucagon-like peptide-1 receptors infee...Xeris Biopharma Holdings, Inc.

    DK grant. $150,930. PI: Samantha Fortin

    full page →nih reporter ↗
    ›Dec 19, 2025grant253d agoUNIVERSITY OF WASHINGTON — MULTI-ETHNIC STUDY OF ATHEROSCLEROSIS (MESA) - TASK AREA AUniversity of Washington

    HL grant. $3,202,749. PI: Robyn Leagh McClelland

    full page →nih reporter ↗
    ›Dec 19, 2025grant253d agoUNIVERSITY OF CALIFORNIA BERKELEY — Leveraging Adaptive Evolution and High-Throughput Techniques to Dissect the L...

    OD grant. $802,500. PI: Margaux Pinney

    full page →nih reporter ↗
    ›Dec 19, 2025grant253d agoNORTHWESTERN UNIVERSITY AT CHICAGO — MULTI-ETHNIC STUDY OF ATHEROSCLEROSIS (MESA) - FIELD CENTERNorthwestern University

    HL grant. $829,413. PI: NORRINA Bai ALLEN

    full page →nih reporter ↗
    ›Dec 19, 2025grant253d agoJOHNS HOPKINS UNIVERSITY — MULTI-ETHNIC STUDY OF ATHEROSCLEROSIS (MESA)Johns Hopkins University

    HL grant. $697,200. PI: WENDY S POST

    full page →nih reporter ↗
    ›Dec 19, 2025grant253d agoUNIVERSITY OF CALIFORNIA LOS ANGELES — MULTI-ETHNIC STUDY OF ATHEROSCLEROSIS (MESA) - FIELD CENTER (FC), TASK AREA AUniversity of California Los Angeles

    HL grant. $674,872. PI: KAROL E WATSON

    full page →nih reporter ↗
    ›Dec 19, 2025grant253d agoWAKE FOREST UNIVERSITY HEALTH SCIENCES — MULTI-ETHNIC STUDY OF ATHEROSCLEROSIS (MESA) - FIELD CENTER, TASK AREA AWake Forest University

    HL grant. $505,956. PI: Alain Gerald Bertoni

    full page →nih reporter ↗
    ›Dec 19, 2025grant253d agoGEORGE WASHINGTON UNIVERSITY — AIDS and Cancer Specimen Resource (ACSR)

    CA grant. $897,500. PI: Jeffrey Michael Bethony

    full page →nih reporter ↗

    Week of Dec 22, 2025

    30
    ›Dec 22, 2025approval250d agoWEGOVY (SEMAGLUTIDE) — FDA approvalNovo Nordisk AS

    Sponsor: NOVO. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Dec 22, 2025approval
    ← prev
    page 15 of 244
    next →
    250d ago
    METHADONE HYDROCHLORIDE — FDA approvalMETHADONE HYDROCHLORIDE

    Sponsor: VISTAPHARM LLC. Form: SOLUTION. Route: ORAL

    full page →METHADONE HYDROCHLORIDE →fda approvals ↗
    ›Dec 22, 2025approval250d agoTRAMADOL HYDROCHLORIDE — FDA approvaltramadol hydrochloride ER

    Sponsor: SPECGX LLC. Form: TABLET. Route: ORAL

    full page →tramadol hydrochloride ER →fda approvals ↗
    ›Dec 22, 2025approval250d agoTRAMADOL HYDROCHLORIDE — FDA approvaltramadol hydrochloride ER

    Sponsor: AUROBINDO PHARMA LTD. Form: TABLET. Route: ORAL

    full page →tramadol hydrochloride ER →fda approvals ↗
    ›Dec 22, 2025approval250d agoOXYCODONE AND ACETAMINOPHEN (ACETAMINOPHEN) — FDA approvalacetaminophen ER

    Sponsor: CHARTWELL. Form: TABLET. Route: ORAL

    full page →acetaminophen ER →fda approvals ↗
    ›Dec 22, 2025approval250d agoPROMETHAZINE WITH CODEINE (CODEINE PHOSPHATE) — FDA approvalCosette Pharmaceuticals Inc

    Sponsor: PHARM ASSOC. Form: SYRUP. Route: ORAL

    full page →fda approvals ↗
    ›Dec 22, 2025approval250d agoOXYCODONE AND ACETAMINOPHEN (ACETAMINOPHEN) — FDA approvalacetaminophen ER

    Sponsor: AUROLIFE PHARMA LLC. Form: TABLET. Route: ORAL

    full page →acetaminophen ER →fda approvals ↗
    ›Dec 22, 2025approval250d agoMETHADONE HYDROCHLORIDE — FDA approvalMETHADONE HYDROCHLORIDE

    Sponsor: VISTAPHARM LLC. Form: TABLET. Route: ORAL

    full page →METHADONE HYDROCHLORIDE →fda approvals ↗
    ›Dec 22, 2025approval250d agoALFENTA (ALFENTANIL HYDROCHLORIDE) — FDA approvalalfentanil hydrochloride

    Sponsor: RISING. Form: INJECTABLE. Route: INJECTION

    full page →alfentanil hydrochloride →fda approvals ↗
    ›Dec 22, 2025approval250d agoHYDROMORPHONE HYDROCHLORIDE — FDA approvalHYDROMORPHONE HYDROCHLORIDE

    Sponsor: HIKMA. Form: SOLUTION. Route: INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS

    full page →HYDROMORPHONE HYDROCHLORIDE →fda approvals ↗
    ›Dec 22, 2025approval250d agoBUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE (BUPRENORPHINE HYDROCHLORIDE) — FDA approvalIGC Pharma, Inc.

    Sponsor: SUN PHARM. Form: TABLET. Route: SUBLINGUAL

    full page →fda approvals ↗
    ›Dec 22, 2025approval250d agoBUTORPHANOL TARTRATE PRESERVATIVE FREE (BUTORPHANOL TARTRATE) — FDA approvalBUTORPHANOL TARTRATE

    Sponsor: HOSPIRA. Form: INJECTABLE. Route: INJECTION

    full page →BUTORPHANOL TARTRATE →fda approvals ↗
    ›Dec 22, 2025approval250d agoPERCOCET (ACETAMINOPHEN) — FDA approvalIGC Pharma, Inc.

    Sponsor: OZANTRI. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Dec 22, 2025approval250d agoMORPHINE SULFATE — FDA approvalTeva Pharmaceuticals USA Inc

    Sponsor: UPSHER SMITH LABS. Form: CAPSULE, EXTENDED RELEASE. Route: ORAL

    full page →fda approvals ↗
    ›Dec 22, 2025approval250d agoFUROSCIX (FUROSEMIDE) — FDA approvalFurosemide Sun

    Sponsor: SCPHARMACEUTICALS. Form: SOLUTION. Route: SUBCUTANEOUS

    full page →Furosemide Sun →fda approvals ↗
    ›Dec 22, 2025approval250d agoMUCINEX 12HR COLD & FEVER MULTI-SYMPTOM (DEXTROMETHORPHAN HYDROBROMIDE) — FDA approvalHetero Labs Ltd

    Sponsor: RB HLTH. Form: TABLET, EXTENDED RELEASE. Route: ORAL

    full page →fda approvals ↗
    ›Dec 22, 2025approval250d agoLEVORPHANOL TARTRATE — FDA approvalLEVORPHANOL TARTRATE

    Sponsor: SPECGX LLC. Form: TABLET. Route: ORAL

    full page →LEVORPHANOL TARTRATE →fda approvals ↗
    ›Dec 22, 2025approval250d agoHYDROCODONE BITARTRATE AND ACETAMINOPHEN (ACETAMINOPHEN) — FDA approvalacetaminophen ER

    Sponsor: WES PHARMA INC. Form: SOLUTION. Route: ORAL

    full page →acetaminophen ER →fda approvals ↗
    ›Dec 22, 2025approval250d agoMEPERIDINE HYDROCHLORIDE — FDA approvalHikma Pharmaceuticals Plc

    Sponsor: GENUS. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Dec 22, 2025approval250d agoHYDROCODONE BITARTRATE AND ACETAMINOPHEN (ACETAMINOPHEN) — FDA approvalIGC Pharma, Inc.

    Sponsor: GENUS. Form: SOLUTION. Route: ORAL

    full page →fda approvals ↗
    ›Dec 22, 2025approval250d agoLEVORPHANOL TARTRATE — FDA approvalLEVORPHANOL TARTRATE

    Sponsor: HIKMA. Form: TABLET. Route: ORAL

    full page →LEVORPHANOL TARTRATE →fda approvals ↗
    ›Dec 22, 2025approval250d agoLEVORPHANOL TARTRATE — FDA approvalLEVORPHANOL TARTRATE

    Sponsor: HIKMA. Form: TABLET. Route: ORAL

    full page →LEVORPHANOL TARTRATE →fda approvals ↗
    ›Dec 22, 2025approval250d agoNUBAIN (NALBUPHINE HYDROCHLORIDE) — FDA approvalTrevi Therapeutics, Inc.

    Sponsor: PH HEALTH. Form: SOLUTION. Route: INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS

    full page →fda approvals ↗
    ›Dec 22, 2025approval250d agoHYDROCODONE BITARTRATE AND ACETAMINOPHEN (ACETAMINOPHEN) — FDA approvalIGC Pharma, Inc.

    Sponsor: SUN PHARM INDS INC. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Dec 22, 2025approval250d agoHYDROCODONE BITARTRATE AND ACETAMINOPHEN (ACETAMINOPHEN) — FDA approvalIGC Pharma, Inc.

    Sponsor: SUN PHARM INDS INC. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Dec 22, 2025approval250d agoFENTANYL-100 (FENTANYL) — FDA approvalZydus Therapeutics Inc

    Sponsor: ZYDUS PHARMS. Form: FILM, EXTENDED RELEASE. Route: TRANSDERMAL

    full page →fda approvals ↗
    ›Dec 22, 2025approval250d agoBUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE (ASPIRIN) — FDA approvalNovitium Pharma LLC

    Sponsor: LGM PHARMA. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗
    ›Dec 22, 2025approval250d agoTRAMADOL HYDROCHLORIDE — FDA approvalTrigen Laboratories Inc

    Sponsor: PURACAP LABS BLU. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Dec 22, 2025approval250d agoACTIQ (FENTANYL CITRATE) — FDA approvalTeva Pharmaceuticals USA Inc

    Sponsor: CEPHALON. Form: TROCHE/LOZENGE. Route: TRANSMUCOSAL

    full page →fda approvals ↗
    ›Dec 22, 2025approval250d agoBUTORPHANOL TARTRATE — FDA approvalBUTORPHANOL TARTRATE

    Sponsor: HIKMA. Form: SPRAY, METERED. Route: NASAL

    full page →BUTORPHANOL TARTRATE →fda approvals ↗
    $XERS8.6000-0.92%
    $BSX46.84+0.36%
    $BSX46.84+0.36%
    $IGC0.2670+0.41%
    $IGC0.2670+0.41%
    $IGC0.2670+0.41%
    $IGC0.2670+0.41%
    $IGC0.2670+0.41%
    $IGC0.2670+0.41%
    $TRVI17.96+0.22%